Clinical Trials Logo

Clinical Trial Summary

This is a randomized controlled trial that uses an audit and feedback intervention to alert primary care physicians who are outliers in one or more metrics related to high risk prescribing of participants' outlier status. Primary care physicians will be randomized to the intervention or control arm, except in California, where all outliers will be notified. The investigators will evaluate the impact of the intervention on prescribing patterns.


Clinical Trial Description

The investigators have developed five different metrics related to low-value (and/or high risk) prescribing habits based on guidelines. The five metrics are listed below. The investigators are using 100% capture Medicare claims data to evaluate the prescribing habits of all US primary care physicians who prescribed to ten or more Medicare patients. A patient is attributed to the primary care physician who prescribed the patient the most medications that year. The investigators have calculated the mean, median, and standard deviation for each of the five metrics based on data from 2016. All primary care physicians who are two or more standard deviation above the mean of a given metric are considered outliers. In each state (excluding California), half of the outliers while be randomly assigned to the intervention group and half will be assigned to the control group, using a random number generator. Those outliers who are assigned to the intervention group will receive a cover letter signed by a members from the Physician Engagement Council (PEC), which is composed of physicians from the Society of General Internal Medicine (SGIM) which explains the study. Participants will also receive a report of participants' status as an outlier which shows in both text and graphic representation, how participants compare to participants' peers. These communications will be sent by mail. The control group will not receive any communication. All outliers in California will receive the intervention. Brief summary of metrics: - Metric 1: Average number of concurrent medications per older patient, by physician - Metric 2: Proportion of older patients who received at least one medication that is a designated high-risk medication in older patients, by physician - Metric 3: Proportion of older patients with concurrent use of multiple central nervous system-active medications, by physician - Metric 4: Proportion of older patients with chronic use of benzodiazepine sedative hypnotic medications, by physician - Metric 5: Proportion of older patients with concurrent use of opioids and benzodiazepines, by physician ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03857100
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase N/A
Start date January 4, 2019
Completion date January 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A